{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:20:52Z","timestamp":1793892052332,"version":"4.8.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T00:00:00Z","timestamp":1612915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s40262-020-00966-z","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T07:26:52Z","timestamp":1612942012000},"page":"819-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine"],"prefix":"10.1007","volume":"60","author":[{"given":"Max","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emel Serap Monkul","family":"Nery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Kerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashna","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen B.","family":"Dennehy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Wilbraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Winner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,10]]},"reference":[{"key":"966_CR1","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1111\/j.1469-8749.2010.03793.x","volume":"52","author":"I Abu-Arafeh","year":"2010","unstructured":"Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies. Dev Med Child Neurol. 2010;52:1088\u201397.","journal-title":"Dev Med Child Neurol."},{"key":"966_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1468-2982.2008.01693.x","volume":"29","author":"D Kernick","year":"2009","unstructured":"Kernick D, Campbell J. Measuring the impact of headache in children: a critical review of the literature. Cephalalgia. 2009;29:3\u201316.","journal-title":"Cephalalgia"},{"key":"966_CR3","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/14656566.2018.1552941","volume":"20","author":"P Barbanti","year":"2019","unstructured":"Barbanti P, Grazzi L, Egeo G. Pharmacotherapy for acute migraines in children and adolescents. Expert Opin Pharmacother. 2019;20:455\u201363.","journal-title":"Expert Opin Pharmacother."},{"key":"966_CR4","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1177\/0333102410370873","volume":"30","author":"DL Nelson","year":"2010","unstructured":"Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, et al. Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia. 2010;30:1159\u201369.","journal-title":"Cephalalgia"},{"key":"966_CR5","unstructured":"Reyvow [prescribing information]. Eli Lilly and Company; 2019. https:\/\/pi.lilly.com\/us\/reyvow-uspi.pdf. Accessed 4 Jun 2020."},{"issue":"2","key":"966_CR6","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1080\/13543784.2017.1280457","volume":"26","author":"M Capi","year":"2017","unstructured":"Capi M, de Andr\u00e9s F, Lionetto L, Gentile G, Cipolla F, Negro A, Borro M, Martelletti P, Curto M. Lasmiditan for the treatment of migraine. Expert Opin Invest Drugs. 2017;26(2):227\u201334.","journal-title":"Expert Opin Invest Drugs."},{"issue":"2","key":"966_CR7","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1080\/14656566.2019.1694004","volume":"21","author":"M Curto","year":"2020","unstructured":"Curto M, Cipolla F, Cisale GY, Capi M, Spuntarelli V, Guglielmetti M, et al. Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother. 2020;21(2):147\u201353.","journal-title":"Expert Opin Pharmacother."},{"key":"966_CR8","doi-asserted-by":"publisher","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","volume":"91","author":"B Kuca","year":"2018","unstructured":"Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91:e2222\u201332.","journal-title":"Neurology."},{"key":"966_CR9","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/brain\/awz134","volume":"142","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142:1894\u2013904.","journal-title":"Brain"},{"key":"966_CR10","doi-asserted-by":"crossref","unstructured":"Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1\u2013211. https:\/\/www.ichd-3.org\/wp-content\/uploads\/2018\/01\/The-International-Classification-of-Headache-Disorders-3rd-Edition-2018.pdf. Accessed 4 Jun 2020.","DOI":"10.1177\/0333102417738202"},{"issue":"10","key":"966_CR11","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1177\/0091270011422812","volume":"52","author":"Y Wang","year":"2012","unstructured":"Wang Y, Jadhav PR, Lala M, Gobburu JV. Clarification on precision criteria to derive sample size when designing pediatric pharmacokinetic studies. J Clin Pharmacol. 2012;52(10):1601\u20136.","journal-title":"J Clin Pharmacol."},{"key":"966_CR12","unstructured":"Centers for Disease Control and Prevention. Data Table of Weight-for-age Charts. https:\/\/www.cdc.gov\/growthcharts\/html_charts\/wtage.htm#males (males) and https:\/\/www.cdc.gov\/growthcharts\/html_charts\/wtage.htm#females (females). Accessed 4 Jun 2020."},{"key":"966_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/jcph.831","volume":"57","author":"T Liu","year":"2017","unstructured":"Liu T, Ghafoori P, Gobburu JVS. Allometry is a reasonable choice in pediatric drug development. J Clin Pharmacol. 2017;57:469\u201375.","journal-title":"J Clin Pharmacol."},{"issue":"5","key":"966_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10928-007-9066-0","volume":"34","author":"RM Savic","year":"2007","unstructured":"Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34(5):711\u201326.","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"966_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/cpdd.768","volume":"9","author":"M Tsai","year":"2020","unstructured":"Tsai M, Case M, Ardayfio P, Hochstetler H, Willbraham D. Effects of lasmiditan on cardiovascular parameters and pharmacokinetics in healthy subjects receiving oral doses of propranolol. Clin Pharmacol Drug Dev. 2020;9:629\u201338.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"5","key":"966_CR16","doi-asserted-by":"publisher","first-page":"e2732","DOI":"10.1002\/hup.2732","volume":"35","author":"EM Pearlman","year":"2020","unstructured":"Pearlman EM, Wilbraham D, Dennehy EB, Berg PH, Tsai M, Doty EG, Kay GG. Effects of lasmiditan on simulated driving performance: results of two randomized, blinded, crossover studies with placebo and active controls. Hum Psychopharmacol. 2020;35(5):e2732. https:\/\/doi.org\/10.1002\/hup.2732.","journal-title":"Hum Psychopharmacol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00966-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-020-00966-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-020-00966-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,11]],"date-time":"2021-06-11T04:53:08Z","timestamp":1623387188000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-020-00966-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["966"],"URL":"https:\/\/doi.org\/10.1007\/s40262-020-00966-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"5 November 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was sponsored by Eli Lilly and Company.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Max Tsai, Emel Serap Monkul Nery, Lisa Kerr, Rashna Khanna, Mika Komori, Ellen B. Dennehy, and Darren Wilbraham are employees and minor stock holders of Eli Lilly and Company. Paul Winner has received research grants, an honorarium, and travel reimbursements from Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All clinical studies described herein have been approved by the appropriate Ethics Committees of all participating centers and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"In this study, a legal representative had to sign a statement of informed consent for a child to participate in the study. In addition to informed consent given by the legal representative, the child may have been required to give documented assent, if capable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated and\/or analyzed during the current study are not publicly available because participants of this study did not agree for their data to be shared publicly.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors participated in the interpretation of the study results and in the drafting, critical revision, and approval of the final version of the manuscript. MT, ESMN, LK, RK, MK, EBD, and DW were involved in the study design, data collection, and data analyses. MT, EBD, RK, MK, and PW were responsible for study monitoring, and MT and LK were responsible for data analysis and plotting.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}